Antibody Details
Product Details
ImmunogenBases 2535-2835 of mouse ROR2 fused in-frame to MBP and expressed in E. coli.
FormulationThis monoclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.2 - 7.4 with no carrier protein or preservatives added.
Product PreparationAntibodies are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and HandlingThis antibody is stable for at least one (1) year at -20°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.
Applications and Recommended Usage?
Quality Tested by LeincoImmunoblotting: use at 1-10ug/mL. A band of ~105kDa is detected.
Immunohistochemistry: use at 1-10ug/mL on paraformaldehyde-fixed, paraffin-embedded sections following antigen retrieval (microwave 12 min in citrate buffer, pH 6.0).
These are recommended concentrations.
Enduser should determine optimal concentrations for their application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Description
Description
SpecificityMouse and human ROR2. Does not cross-react with ROR1.
BackgroundReceptor tyrosine kinases (RTKs) are cell surface receptors that regulate normal cellular processes through ligand-controlled tyrosine kinase activity. ROR2 is a membrane-bound RTK that is activated by Wnt signaling during normal bone and cartilage development. Recently, ROR2 has been shown to have pro-tumorigenic effects in osteosarcoma, melanoma, and renal cell carcinoma cell lines. ROR2 levels have also been described in soft-tissue sarcomas; specifically, in vitro studies revealed that invasive abilities of leiomyosarcoma (LMS) and gastrointestinal stromal tumor (GIST) are affected by ROR2 expression, and suppression of ROR2 reduces in vivo tumor mass in a xenotransplantation model of LMS.
FunctionTyrosine-protein kinase receptor which may be involved in the early formation of the chondrocytes. It seems to be required for cartilage and growth plate development (By similarity). Phosphorylates YWHAB, leading to induction of osteogenesis and bone formation (PubMed:17717073). In contrast, has also been shown to have very little tyrosine kinase activity in vitro. May act as a receptor for wnt ligand WNT5A which may result in the inhibition of WNT3A-mediated signaling (PubMed:25029443). {UniProtKB:Q9Z138, PubMed:17717073, PubMed:25029443}.
References & Citations
1) Mikels A et al. 2009 J Biol Chem 284: 30167-30176.
2) Wright TM et al. 2009 Oncogene 28: 2513-2523.
3) Edris B et al. 2012 J Pathol 227: 223-233
4) ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target. Sci Rep (2020) [32807831]
Certificate of Analysis